Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group

Rena BucksteinSunnybrook Health Sciences Center, Toronto, ON, CanadaCorrespondence[email protected]

John KuruvillaDepartment of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada

Neil ChuaCross Cancer Institute, Edmonton, AB, Canada

Christina LeeSunnybrook Health Sciences Center, Toronto, ON, Canada

David A. MacdonaldQEII Health Sciences Centre, Halifax, NS, Canada

Abdulwahab J. Al-tourahBC Cancer Center-Fraser Valley Center, Surrey, BC, Canada

Alison H. FooNCIC Clinical Trials Group, Kingston, ON, Canada

Wendy WalshNCIC Clinical Trials Group, Kingston, ON, Canada

S. Percy ivyNational Cancer Institute, Rockville, MD, USA

Michael CrumpMedical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada

Elizabeth A. EisenhauerNCIC Clinical Trials Group, Kingston, ON, Canada

Your download is now in progress and you may close this window